抄録検索

検索結果

PAGE : [1]      <<      175   |   176   |   177   |   178   |   179   |   180   |   181      >>      [184]
検索結果 178/184ページ目を表示(合計:1836件)

第56回・2018年・横浜

FACO Poster Session

FACO Poster Session 2
FACO Poster Session 2

演題番号 : FP2-11

Lymph node status guides taxane-based escalating and de-escalating chemotherapy in patients with early triple negative breast cancer

Speaker）Sanxing Guo:1、Suzhi Zhang:2、Na Wang:3、Yujie He:4、Xingya Li:1
1:Oncology Department, The First Affiliated Hospital of Zhengzhou University, China、2:Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, China、3:Department of Radiotherapy, The First Affiliated Hospital of Zhengzhou University, China、4:Rheumatology and Immunology Department, The First Affiliated Hospital of Zhengzhou University, China

抄録

第56回・2018年・横浜

FACO Poster Session

FACO Poster Session 2
FACO Poster Session 2

演題番号 : FP2-12

The combination of NVP-BEZ235 and endostatin exerts synergistic anticancer activity against triple-negative breast cancer in vitro and in vivo

Speaker）Xiaoshan Wang:1、Xiao Zhang:2、Fanghua Li:3
1:Cancer Center, Sichuan Provincial People Hospital, University of Electronic Science and Technology of China, China、2:Department of Breast Surgery, Sichuan Provincial People Hospital, University of Electronic Science and Technology of China, China、3:Department of Pathology, Sichuan Provincial People Hospital, University of Electronic Science and Technology of China, China

抄録

第56回・2018年・横浜

FACO Poster Session

FACO Poster Session 2
FACO Poster Session 2

演題番号 : FP2-13

Fulvestrant 500mg versus Exemestane in postmenopausal Metastatic Breast Cancer (MBC) resistant to adjuvant Non-steroidal Aromatase Inhibitors (NSAI) in clinical practice

Speaker）Yizhao Xie:1、Biyun Wang:1、Yannan Zhao:1、Chengcheng Gong:1、Yi Li:1、Xichun Hu:1、Jian Zhang:1、Leiping Wang:1
1:Medical Oncology, Fudan University Shanghai Cancer Center, China

抄録

第56回・2018年・横浜

FACO Poster Session

FACO Poster Session 2
FACO Poster Session 2

演題番号 : FP2-14

Cost-effectiveness analysis of bevacizumab plus paclitaxel versus bevacizumab plus capecitabine for HER2-negative metastatic breast cancer

Speaker）Qiuji Wu:1、Qiu Li:1
1:Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, China

抄録

第56回・2018年・横浜

FACO Poster Session

FACO Poster Session 2
FACO Poster Session 2

演題番号 : FP2-15

Concordance assessment of IBM Watson for oncology with MDT in patients with breast cancer

Speaker）Junnan Xu:1,2、Tao Sun:1,2
1:Department of Medical Onocolgy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, China、2:Key Laboratory of Liaoning Breast Cancer Research, China

抄録

第56回・2018年・横浜

FACO Poster Session

FACO Poster Session 2
FACO Poster Session 2

演題番号 : FP2-16

演題取り下げ

抄録

第56回・2018年・横浜

FACO Poster Session

FACO Poster Session 2
FACO Poster Session 2

演題番号 : FP2-17

演題取り下げ

抄録

第56回・2018年・横浜

FACO Poster Session

FACO Poster Session 2
FACO Poster Session 2

演題番号 : FP2-18

演題取り下げ

抄録

第56回・2018年・横浜

FACO Poster Session

FACO Poster Session 2
FACO Poster Session 2

演題番号 : FP2-19

Postoperative micropapillary lung adenocarcinoma patients have higher rates of vascular cancer thrombi, bronchial invasion and positive ALK fusion protein

Speaker）Shaomei Li:1、Cuicui Zhang:1、Qiming Wang:1
1:Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou University, China

抄録

第56回・2018年・横浜

FACO Poster Session

FACO Poster Session 2
FACO Poster Session 2

演題番号 : FP2-20

演題取り下げ

抄録
PAGE : [1]      <<      175   |   176   |   177   |   178   |   179   |   180   |   181      >>      [184]